RxDoctor Payments DataLook up a doctor →

Kimberly Workowski, MD

Infectious Disease · Atlanta, GANPI 1588676712

Payments from drug & device makers

$2,024,557in general payments, 2019–2025

Across 366 payments — averaging $5531.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1.6M
  • AbbVie$318K
  • GSK$73K
  • Janssen Scientific Affairs, LLC$13K
  • Viiv Healthcare Company$8K
  • Merck$5K
  • plus $2K from 1 others

What the payments were for

  • Consulting fees$48,82092%
  • Speaking & faculty fees$1,6083%
  • Travel & lodging$1,9604%
  • Food & beverage$6711%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead277$1,605,563
AbbVie36$318,495
GSK19$72,590
Janssen Scientific Affairs, LLC24$13,301
Viiv Healthcare Company7$7,749
Merck1$5,090
La Jolla Pharmaceutical Company2$1,769

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,024,557 in reported general payments places this provider in the 95th percentile of 260 infectious disease providers in Georgia.

See all infectious disease providers in Georgia

Medicare billing

Part B allowed, 2024
$18,677
Medicare patients
66
Services billed
182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala377$1,478,300
TivicayDolutegravir Sodium217$489,547
TriumeqAbacavir/Dolutegravir/Lamivudi100$375,643
DescovyEmtricitabine/Tenofov Alafenam123$269,007
GenvoyaElviteg/Cob/Emtri/Tenof Alafen56$226,834
PrezcobixDarunavir/Cobicistat83$193,081
StribildElviteg/Cob/Emtri/Tenofo Disop36$133,039
IsentressRaltegravir Potassium48$87,474
CompleraEmtricita/Rilpivirine/Tenof Df25$75,181
PrezistaDarunavir35$69,722
OzempicSemaglutide51$52,169
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df38$42,739
DovatoDolutegravir Sodium/Lamivudine13$38,073
IntelenceEtravirine12$17,655
VemlidyTenofovir Alafenamide12$17,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya, Stribild, Vemlidy$1,605,563$2,124,402604 claims
Viiv Healthcare CompanyTivicay, Triumeq, Dovato$7,749$903,263330 claims
MerckIsentress$5,090$87,47448 claims
Janssen Scientific Affairs, LLCPrezista, Intelence$13,301$87,37747 claims
AbbVieLinzess$318,495$6,53212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 260 infectious disease providers in Georgia.

Other infectious disease in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →